Clinical-immunological Features of Anti-NMDAR Encephalitis
- Conditions
- Anti NMDA Receptor Encephalitis
- Interventions
- Other: Description of clinical characteristic
- Registration Number
- NCT05738668
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Not specified
- Target Recruitment
- 400
- Patient with neurological disorder
- Patient with NMDAR antibodies in sera or CSF
-
- No available clinical data
- Patient without NMDAR antibodies or neurological disorder
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Anti-NMDAR encephalitis Description of clinical characteristic Patients with well-characterized anti-NMDAR encephalitis.
- Primary Outcome Measures
Name Time Method Modified Rankin scale (mRS) Baseline Scale for measuring the degree of dependence in the daily activities of people who have suffered of neurological disability.
0 - No symptoms.
1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
3. - Moderate disability. Requires some help, but able to walk unassisted.
4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
6. - Dead.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est
🇫🇷Lyon, Bron, France